Real-world examples of how our expertise has helped partners advance their programs.
A shift to a four-arm, multi-dose Phase IIa protocol introduced new requirements for dosing accuracy, traceability, and patient usability. Learn how Ardena designed a modular secondary packaging solution that integrated existing blister configurations and enabled seamless execution of the updated clinical design.
Long-acting biologics present specific challenges for immunogenicity assessment, particularly when residual drug interferes with ADA detection. In this case study, Ardena outlines how a drug-tolerant ADA assay was established for a high-dose monoclonal antibody, enabling reliable detection in samples with high circulating drug levels. Discover how targeted optimisation of a PandA-based approach delivered a robust, […]
Case study A highly promising analogue of an endogenous protein was identified as a drug candidate in preclinical studies in rats and monkeys. The sponsor decided to proceed with clinical studies in humans within 10 months, which was a major challenge as the data on immunogenicity required for the regulatory IND filing had to be […]
Case study Drug repurposing has become a rich source of safe and effective new therapeutic options against unmet medical needs. With the appearance of SARS CoV2 and the pandemic spread of severe Covid-19, drug repurposing has intensively being used to identify potential new drug candidates. One of the potential drug candidates was a small molecule […]
Case study: Building discriminatory power into dissolution testing in late development – a key milestone for the fast product approval Dissolution testing was introduced into pharmaceutical practice after the occurrence of serious side effects of phenytoin after calcium sulfate was replaced by lactose. As a result, the FDA introduced the USP Dissolution type 1 (Basket […]
